MSCI ACWI IMI Immuno-oncology Index (USD)

The MSCI ACWI IMI Immuno-oncology Index (the 'Index') aims to represent the performance of a set of companies that are associated with research, development, and commercialization of products for cancer immunotherapy, also known as Immuno-oncology. Immuno-oncology is a form of cancer treatment that uses the power of the body's own immune system to prevent, control and eliminate cancer.

For a complete description of the index methodology, please see Index methodology - MSCI.

CUMULATIVE INDEX PERFORMANCE — NET RETURNS (USD) (NOV 2016 – MAR 2025)



ANNUAL PERFORMANCE (%)

| Year | MSCI ACWI IMI Immuno-oncology | MSCI ACWI IMI |
|------|----------------------------------|---------------|
| 2024 | 0.27 | 16.37 |
| 2023 | -6.35 | 21.58 |
| 2022 | -5.75 | -18.40 |
| 2021 | -2.65 | 18.22 |
| 2020 | 29.44 | 16.25 |
| 2019 | 20.44 | 26.35 |
| 2018 | -2.96 | -10.08 |
| 2017 | 29.90 | 23.95 |
| | | |

INDEX PERFORMANCE - NET RETURNS (%) (MAR 31, 2025)

FUNDAMENTALS (MAR 31, 2025)

| | | | | | ANNUALIZED | | | | | | | |
|-----------------------------------|-------|-------|------|-------|------------|-------|-------|-----------------------|-------------|-------|---------|------|
| | 1 Mo | 3 Мо | 1 Yr | YTD | 3 Yr | 5 Yr | 10 Yr | Since Nov 30, 2016 | Div Yld (%) | P/E | P/E Fwd | P/BV |
| MSCI ACWI IMI Immuno- oncology | -1.88 | 5.46 | 0.86 | 5.46 | -0.15 | 4.90 | na | 7.36 | 2.45 | 34.89 | 21.59 | 4.23 |
| MSCI ACWI IMI | -3.88 | -1.61 | 6.30 | -1.61 | 6.31 | 15.02 | na | 10.19 | 1.96 | 20.67 | 16.97 | 2.83 |

ANNULALIZED

INDEX RISK AND RETURN CHARACTERISTICS (NOV 30, 2016 - MAR 31, 2025)

| | | | | ANNUALIZED STD DEV (%) 2 | | | | | | MAXIMUM DRAWDOWN | | |
|-----------------------------------|-------------------|-----------------------|------------------------------|--------------------------|-------------|-------|-----------------------|-----------|------------|--------------------------|--------------|---------------------------------|
| | Beta | Tracking Error (%) | Turnover (%) ¹ | 3 Yr | 5 Yr | 10 Yr | 3 Yr | 5 Yr | 10 Yr | Since Nov 30, 2016 | (%) | Period YYYY-MM-DD |
| MSCI ACWI IMI Immuno- oncology | 0.72 | 12.40 | 35.18 | 15.18 | 16.62 | na | -0.21 | 0.21 | na | 0.38 | 29.25 | 2021-01-20-2023-10-27 |
| MSCI ACWI IMI | 1.00 | 0.00 | 2.30 | 16.45 | 16.02 | na | 0.20 | 0.79 | na | 0.56 | 34.52 | 2020-02-12-2020-03-23 |
| | ¹ Last | 12 months | ² Based o | n monthly | net returns | data | ³ Based on | NY FED Ov | ernight SO | FR from Se | p 1 2021 & d | on ICE LIBOR 1M prior that date |

The MSCI ACWI IMI Immuno-oncology Index was launched on Mar 06, 2023. Data prior to the launch date is back-tested test (i.e. calculations of how the index might have performed over that time period had the index existed). There are frequently material differences between back-tested performance and actual results. Past performance – whether actual or back-tested – is no indication or guarantee of future performance.



^{1 -} https://www.cancerresearch.org/what-is-immunotherapy

MAR 31, 2025 **Index Factsheet**


INDEX CHARACTERISTICS

| | MSCI ACWI IMI Immuno-oncology | MSCI ACWI IMI | | | | |
|---------------------|----------------------------------|---------------|--|--|--|--|
| Number of | 45 | 8,406 | | | | |
| Constituents | | | | | | |
| | Weight (%) | | | | | |
| | | | | | | |
| Largest | 6.29 | 3.93 | | | | |
| Largest Smallest | 6.29 0.04 | 3.93 0.00 | | | | |
| • | 0.25 | | | | | |

TOP 10 CONSTITUENTS

| | Country | Index Wt. (%) | Parent Index Wt. (%) |
|-------------------------|---------|------------------|-------------------------|
| ABBVIE | US | 6.29 | 0.44 |
| GILEAD SCIENCES | US | 6.19 | 0.16 |
| ASTRAZENECA | GB | 5.76 | 0.27 |
| ROCHE HOLDING GENUSS | CH | 5.64 | 0.27 |
| JOHNSON & JOHNSON | US | 5.54 | 0.47 |
| NOVARTIS | CH | 5.44 | 0.26 |
| BRISTOL-MYERS SQUIBB CO | US | 5.34 | 0.15 |
| AMGEN | US | 5.29 | 0.20 |
| PFIZER | US | 4.85 | 0.17 |
| GSK | GB | 4.66 | 0.09 |
| Total | | 55.00 | 2.47 |

FACTORS - KEY EXPOSURES THAT DRIVE RISK AND RETURN **MSCI FACTOR BOX**



MSCI FaCS



VALUE Relatively Inexpensive Stocks



LOW SIZE Smaller Companies



MOMENTUM Rising Stocks



QUALITY Sound Balance Sheet Stocks



YIELD Cash Flow Paid Out




LOW VOLATILITY Lower Risk Stocks

MSCI FaCS provides absolute factor exposures relative to a

broad global index - MSCI ACWI IMI.

Neutral factor exposure (FaCS = 0) represents MSCI ACWI IMI.

SUB-INDUSTRY WEIGHTS





MAR 31, 2025 Index Factsheet

MSCI FACTOR BOX AND FaCS FRAMEWORK (Please refer to complete description of the MSCI FaCS methodology here)

MSCI FaCS is a standard method for evaluating and reporting the Factor characteristics of equity portfolios. MSCI FaCS consists of Factor Groups (e.g. Value, Size, Momentum, Quality, Yield, and Volatility) that have been extensively documented in academic literature and validated by MSCI Research as key drivers of risk and return in equity portfolios. These Factor Groups are constructed by aggregating 16 factors (e.g. Book-to-Price, Earnings/Dividend Yields, LT Reversal, Leverage, Earnings Variability/Quality, Beta) from the latest Barra global equity factor risk model, GEMLT, designed to make fund comparisons transparent and intuitive for use. The MSCI Factor Box, which is powered by MSCI FaCS, provides a visualization designed to easily compare absolute exposures of funds/indexes and their benchmarks along 6 Factor Groups that have historically demonstrated excess market returns over the long run.

ABOUT MSCI

MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 45 years of expertise in research, data and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process. To learn more, please visit www.msci.com.

The information contained herein (the "Information") may not be reproduced or redisseminated in whole or in part without prior written permission from MSCI. The Information may not be used to verify or correct other data, to create indexes, risk models, or analytics, or in connection with issuing, offering, sponsoring, managing or marketing any securities, portfolios, financial products or other investment vehicles. Historical data and analysis should not be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information or MSCI index or other product or service constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy. Further, none of the Information or any MSCI index is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. The Information is provided "as is" and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information. NONE OF MSCI INC. OR ANY OF ITS SUBSIDIARIES OR ITS OR THEIR DIRECT SUPPLIERS OR ANY THIRD PARTY INVOLVED IN THE MAKING OR COMPILING OF THE INFORMATION (EACH, AN "MSCI PARTY") MAKES ANY WARRANTIES OR REPRESENTATIONS AND, TO THE MAXIMUM EXTENT PERMITTED BY LAW, EACH MSCI PARTY HEREBY EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING WARRANTIES OR MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.WITHOUT LIMITING ANY OF THE FOREGOING AND TO THE MAXIMUM EXTENT PERMITTED BY LAW, IN NO EVENT SHALL ANY OF THE MSCI PARTY! SHOULD ANY DIRECT, INDIRECT, SPECIAL, PUNITIVE, CONSEQUENTIAL (INCLUDING LOST PROFITS) OR ANY OTHER DAMAGES EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES. The foregoing shall not exclude or limit any liability that may not by applicable law be excluded or limited.

© 2025 MSCI Inc. All rights reserved.

